

Gibson Dunn Advises Arrowhead Pharmaceuticals on Signing of Asset Purchase Agreement Between Sanofi and Visirna Therapeutics

Firm News | August 11, 2025

Gibson Dunn represented Arrowhead Pharmaceuticals on the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. Under the terms, Sanofi will acquire rights to develop and commercialize investigational plozasiran in Greater China. Visirna will receive an upfront payment of \$130 million from Sanofi and is eligible to receive further milestone payments of up to \$265 million. Arrowhead is further eligible to receive royalties on net commercial product sales of plozasiran in Greater China as part of the Arrowhead-Visirna license agreement assigned in part to Sanofi.

Gibson Dunn regularly advises life sciences companies on complex cross-border transactions and strategic licensing arrangements in the biopharmaceutical sector.

The Gibson Dunn team was led by Karen Spindler, Jin Hee Kim, Paul Rafla, and Sonari Chidi. Pamela Endreny and Ryan Rott are advising on tax aspects; Cassandra Gaedt-Sheckter and Courtney Wang are advising on data privacy aspects; and John Partridge and Ning Ning are advising on compliance aspects.

Related People

[Karen A. Spindler](#)

[Jin Hee Kim](#)

[Paul Rafla](#)

[Sonari Chidi](#)

[Pamela Lawrence Endreny](#)

[Ryan Rott](#)

[Cassandra L. Gaedt-Sheckter](#)

[Courtney Wang](#)

[John D.W. Partridge](#)

[Ning Ning](#)

Related Capabilities

[Intellectual Property](#)

[Life Sciences](#)

[Finance](#)

[Tax](#)

[Privacy, Cybersecurity, and Data Innovation](#)